Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
20%
Ph phase_2
8
80%

Phase Distribution

2

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
8(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Terminated(1)

Detailed Status

Completed9
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (20.0%)
Phase 28 (80.0%)

Trials by Status

withdrawn110%
completed990%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC

NCT00432185
withdrawnphase_1

The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)

NCT00546611
completedphase_2

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

NCT00375739
completedphase_2

A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel

NCT00427050
completedphase_2

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses

NCT00107965
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00432185Phase 2

To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC

Completed
NCT00546611Phase 1

The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)

Withdrawn
NCT00375739Phase 2

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

Completed
NCT00427050Phase 2

A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel

Completed
NCT00107965Phase 2

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic Keratoses

Completed
NCT00239135Phase 2

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

Completed
NCT00544258Phase 1

Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005

Completed
NCT00329121Phase 2

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ

Completed
NCT00108121Phase 2

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma

Completed
NCT00108134Phase 2

Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10